On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, sparking ...

近日，天士力自主研发的同种异体脂肪间充质基质细胞注射液（NR-20201）获国家药品监督管理局药品审评中心（CDE）批准开展临床，治疗急性缺血性脑卒中。这是CDE批准的国内首款间充质基质细胞药的临床试验申请 ...

近期，国际学术期刊ACS Nano在线发表了石鹏教授团队以“Adhesion-assisted antioxidant-engineered mesenchymal stromal cells for enhanced cardiac repair ...

2012年，美国FDA拒绝了Osiris的骨髓来源药物Prochymal的上市申请。其宣称的干细胞修复机制与其临床数据脱节，且缺乏可验证的效力测定方法支持。这一结论在Osiris的2012年SEC文件与美国FDA 2017年细胞治疗指南中均有迹可循。这一失败揭示了关键问题：缺乏有效的效力测定、未见明确的作用机制以及未证实MSC在体内发挥"干细胞"的分化能力。

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

Scientists have uncovered a hidden driver of ovarian cancer—high-risk mesenchymal stem cells lurking in the fallopian tubes.

At its third attempt, Mesoblast has secured FDA approval for Ryoncil as a treatment for children with graft-versus-host disease, the first-ever approval for a mesenchymal stromal cell (MSC ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...

Researchers at the University of Pittsburgh have identified a novel trigger for a deadly form of ovarian cancer: a subset of ...

Researchers at the University of Pittsburgh have identified a novel trigger of a deadly form of ovarian cancer: a subset of ...

Pitt research uncovers new insights into ovarian cancer origins, shedding light on potential early detection and treatment ...